1757-4684/asset/olbannerleft.jpg?v=1&s=bbd2e0b80f5732e6debc8359b97d6dd36437820d)
1757-4684/asset/olbannerright.jpg?v=1&s=b2a7dc2c527cdc2509c695006f69ea9f80aaab1a)
Report
You have full text access to this OnlineOpen article
Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
Article first published online: 18 NOV 2009
DOI: 10.1002/emmm.200900048
Copyright © 2009 EMBO Molecular Medicine
1757-4684/asset/cover.gif?v=1&s=f0ae6ba1c75dc3c8ab91b28fcfb5cf75613dca6f "EMBO Molecular Medicine")
Additional Information
How to Cite
Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C. and Holtzman, D. M. (2009), Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Mol Med, 1: 371–380. doi: 10.1002/emmm.200900048
Publication History
- Issue published online: 26 NOV 2009
- Article first published online: 18 NOV 2009
- Manuscript Accepted: 23 SEP 2009
- Manuscript Revised: 8 SEP 2009
- Manuscript Received: 16 JUN 2009
Funded by
- National Institute of Aging of the National Institutes of Health. Grant Numbers: P50 AG05681, P01 AG03991, P01 AG026276, P30 NS057105
- National Institute of Neurological Disorders and Stroke. Grant Number: P30 NS048056
- National Center for Research Resources, NIH Roadmap for Medical Research. Grant Number: UL1 RR024992
- Dana Foundation
- Charles and Joanne Knight Alzheimer Research Initiative
- Abstract
- Article
- References
- Cited By
Cited in:
This article has been cited by:
- 1, , Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?, Biochemical Pharmacology, 2013, 85, 3, 289
- 2, , Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis, Medical Clinics of North America, 2013, 97, 3, 377
- 3, , , , , , , , , , , , , Brain injury biomarkers are not dependent on β-amyloid in normal elderly, Annals of Neurology, 2013, 73, 4Direct Link:
- 4, , , Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker, Alzheimer's Research & Therapy, 2013, 5, 2, 8
- 5, , , , , , , , , , , , Preliminary Study for a Multicenter Study of Alzheimer's Disease Cerebrospinal Fluid Biomarkers, Dementia and Neurocognitive Disorders, 2013, 12, 1, 1
- 6, , , , , , , , , , , , , , Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, The Lancet Neurology, 2013, 12, 2, 207
- 7, Alzheimer's disease diagnostic criteria: practical applications, Alzheimer's Research & Therapy, 2012, 4, 4, 35
- 8, , Alzheimer's Disease: Redox Dysregulation As a Common Denominator for Diverse Pathogenic Mechanisms, Antioxidants & Redox Signaling, 2012, 16, 9, 974
- 9, , , , , , , , , , , , , , An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease, Annals of Neurology, 2012, 71, 6Direct Link:
- 10, , Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough, Imaging in Medicine, 2012, 4, 3, 343
- 11, , , , , , , , , , , , , , , Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers, AIDS, 2012, 26, 18, 2327
- 12, , , , , , , Cerebrospinal Fluid Proteins Predict Longitudinal Hippocampal Degeneration in Early-stage Dementia of the Alzheimer Type, Alzheimer Disease & Associated Disorders, 2012, 26, 4, 314
- 13, , , , , , CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer’s pathological cascade, Brain Imaging and Behavior, 2012, 6, 4, 599
- 14, CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease, Journal of Molecular Neuroscience, 2012, 47, 1, 1
- 15, , , , , Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer’s disease and other neurodegenerative dementias, European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, S2, 71
- 16, , , , , , , Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of -Amyloid in Mice with Alzheimer's Disease Pathology, Science Translational Medicine, 2012, 4, 150, 150ra122
- 17, , , , , , , , , , , , Effect of lifestyle activities on alzheimer disease biomarkers and cognition, Annals of Neurology, 2012, 72, 5Direct Link:
- 18
- 19, , , PET amyloid-beta imaging in preclinical Alzheimer's disease, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012, 1822, 3, 370
- 20, , , , Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors, Pharmacology & Therapeutics, 2012, 134, 1, 8
- 21, , , , Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals, BMC Medicine, 2012, 10, 1, 127
- 22, , Relative contributions of biomarkers in Alzheimer’s disease, Annals of Epidemiology, 2012, 22, 12, 868
- 23, , , , , , , , , , , , Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative, Alzheimer's & Dementia, 2012, 8, 1, 65
- 24, The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization, Chemical Reviews, 2012, 112, 10, 5147
- 25, , , , , Toward a multifactorial model of Alzheimer disease, Neurobiology of Aging, 2012, 33, 10, 2262
- 26, , , Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI, Human Brain Mapping, 2012, 33, 11Direct Link:
- 27, , Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer’s disease, Biomarkers in Medicine, 2012, 6, 4, 455
- 28
- 29, , , Alzheimer's Disease: The Challenge of the Second Century, Science Translational Medicine, 2011, 3, 77, 77sr1
- 30, Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia, Neurobiology of Aging, 2011, 32, S20
- 31, Amyloid imaging for Alzheimer's disease, Expert Opinion on Medical Diagnostics, 2011, 5, 6, 527
- 32, , , , , , , Biomarkers associated with delirium in critically ill patients and their relation with long-term subjective cognitive dysfunction; indications for different pathways governing delirium in inflamed and noninflamed patients, Critical Care, 2011, 15, 6, R297
- 33, , Biomarkers Predicting Alzheimer's Disease in Cognitively Normal Aging, Journal of Clinical Neurology, 2011, 7, 2, 60
- 34, , , , , , , , , , , Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid ß-Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas, Biological Psychiatry, 2011, 70, 2, 183
- 35, CSF biomarkers for Alzheimer's disease: current utility and potential future use, Neurobiology of Aging, 2011, 32, S4
- 36, CSF biomarkers in neurodegenerative diseases, Clinical Chemistry and Laboratory Medicine, 2011, 49, 3
- 37, , , Developing predictive CSF biomarkers—A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine, Biochemical Pharmacology, 2011, 81, 12, 1422
- 38, , , , , , , , , , , , , , , Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI, Acta Neuropathologica, 2011, 122, 4, 401
- 39, Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development, Alzheimer's Research & Therapy, 2011, 3, 6, 34
- 40, , PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease, Alzheimer's Research & Therapy, 2011, 3, 2, 11
- 41, , , The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics, Nature Reviews Drug Discovery, 2011, 10, 9, 698
- 42, , , , , , , , TOMM40 poly-T Variants and Cerebrospinal Fluid Amyloid Beta Levels in the Elderly, Neurochemical Research, 2011, 36, 6, 1124
- 43, , , , , , , , , , , , Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid, Alzheimer's & Dementia, 2011, 7, 2, 133
- 44, , , , , , , , , , , , , Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer disease, Annals of Neurology, 2011, 70, 2Direct Link:
- 45, , , , , , , , , , , , , , Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease, Acta Neuropathologica, 2010, 120, 3, 385
- 46, , , , , , , , Biomarkers for the Early Stages of Clinical Development in Alzheimer’s Disease, Thérapie, 2010, 65, 4, 285
- 47, , Biomarkers in translational research of Alzheimer’s Disease, Neuropharmacology, 2010, 59, 4-5, 310
- 48, , , , , , , , Biomarqueurs aux phases précoces de développement dans la maladie d’Alzheimer, Thérapie, 2010, 65, 4, 277
- 49, , , , Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nature Reviews Neurology, 2010, 6, 3, 131
- 50, , Cerebrospinal fluid biomarkers of Alzheimer’s disease, Biomarkers in Medicine, 2010, 4, 1, 51
- 51, , , , , , , , , , , , , CSF Aβ42 and tau in Parkinson's disease with cognitive impairment, Movement Disorders, 2010, 25, 15Direct Link:
- 52, , , , , , , , , From the Cover: Spatial correlation between brain aerobic glycolysis and amyloid- (A ) deposition, Proceedings of the National Academy of Sciences, 2010, 107, 41, 17763
- 53, , Quantitative structural MRI for early detection of Alzheimer’s disease, Expert Review of Neurotherapeutics, 2010, 10, 11, 1675
- 54, , , , , Relationship of dementia screening tests with biomarkers of Alzheimer's disease, Brain, 2010, 133, 11, 3290
- 55, , , , , , , , , , , , , , , , , , YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease, Biological Psychiatry, 2010, 68, 10, 903
- 56, , , , , Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2010, 41, 3, 101